目的研究和改进甲磺酸伊马替尼的合成工艺。
OBJECTIVE To study and improve the synthesis of imatinib mesylate.
翻译过来就是，诺华在全球出售伊马替尼的价格搞的我相当的不爽！
However, the price at which imatinib has been offered for sale by Novartis around the world has caused me considerable discomfort.
我们对接受伊马替尼作为初始治疗的CML患者进行了5年的随访。
For 5 years, we followed patients with CMLwho received imatinib as initial therapy.
在进行死因分析时，接受伊马替尼治疗的患者的总体生存率为88%。
The estimated overall survival rate for patients receiving Gleevec was 88% when considering deaths from all causes.
在治疗的第一年到第六年之间，伊马替尼治疗的累积最佳应答率显著提高。
Cumulative best responses to Gleevec treatment improved dramatically between the first and sixth years of treatment.
应用伊马替尼对包含该突变体的肿瘤进行分子靶向治疗，多数患者表现为药物抵抗。
The most GISTs are drug-resistant when be treated with imatinib which is a molecular targeted drug.
这些数据表明，伊马替尼治疗可能是一种治疗人类冷球蛋白血症和MPGN的新方法。
These data suggest that treatment with imatinib may be a novel therapeutic approach for cryoglobulinemia and MPGN in humans.
在全部192例患者中，129例完成研究，58例接受间断治疗，26例接受持续伊马替尼治疗。
Of the 192 patients recruited, 129 completed the study; 58 received intermittent treatment and 26 received continuous imatinib treatment.
目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
用伊马替尼治疗的慢性粒细胞白血病（CML）患者血浆脂联素浓度显著升高：这是改善2型糖尿病CML患者胰岛素敏感性的一种机制？
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
包括药物的发明者BrianDruker博士在内的一个由来自美国和欧洲的研究人员组成的团队跟踪研究了454位慢性粒细胞性白血病慢性期患者，这些患者使用伊马替尼已经超过6年。
A team of researchers from the U. s. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years.
包括药物的发明者BrianDruker博士在内的一个由来自美国和欧洲的研究人员组成的团队跟踪研究了454位慢性粒细胞性白血病慢性期患者，这些患者使用伊马替尼已经超过6年。
A team of researchers from the U. s. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years.
应用推荐